Ab-initio pharma | Formulation and GMP product manufacturing services for clinical trials in Australia
Australia has an increasing demand for specialist contract formulation and manufacturing facilities to provide bespoke pharmaceutical products that meet regulatory and quality control standards.
The project will establish a unique and specialist manufacturing and training facility, Ab-initio, that provides cost effective manufacturing solutions for small-medium-enterprises (SMEs), academics, clinicians and larger pharma for early phase clinical trials in Australia. The consortium members hope that this project will assist Australia’s position as a global leader in the pharmaceutical sector.
Outcomes: Facility has been built and is waiting for the final equipment and hand-over. Nine staff have been employed. The facility will progress TGA certification once complete.
| State | New South Wales |
| Consortium Lead | The University of Sydney |
| Consortium Members | Ab Initio Pharma, Sydney Local Health District (SLHD) & ARCS Australia |
| MTPConnect Grant | $500,000 |
| Industry Contribution | $716,198 |
| State Government Contribution | $200,000 |
| Project Duration | July 2018 - October 2021 (Ongoing) |
| Contact | Paul Young, Ab Initio - paul.young@ab-initio-pharma.com |
Visit The University of Sydney & Ab-Initio-Pharma for more information.
Twitter: Sydney_Uni & @AbinitioPharma | LinkedIn: The University of Sydney & Ab Initio Pharma